Novel lipopeptide vesicles are prepared from self-assembled nanomembranes through an extrusion method. The size of vesicles can be controlled by the pore diameter of the extrusion filter. The vesicles are rather stable because hydrogen bonds exist among the peptide headgroups. When doxorubicin hydrochloride (DOX·HCl) is encapsulated in the vesicles, it could be released sustainably, and its side effect would also be reduced due to encapsulation. The leakage rate of DOX·HCl depends on the pH via charge regulation. As drug carriers, lipopeptide vesicles have been proved to have nontoxicity to normal cells. A magnetic surfactant CH3(CH2)14CH2N(CH3)3+ [FeCl3Br]- (CTAFe) was mixed with lipopeptide to modify the vesicles. Also, the results demonstrated that the vesicles is endowed with magnetic property after the addition of CTAFe. We believe that the strategy of lipopeptide vesicle preparation would enrich the drug carrier family and expand the application of lipopeptide materials.